Fusion Antibodies

Fusion Antibodies PLC is a specialized contract research organization (CRO) providing comprehensive antibody discovery, engineering, and cell line development services to biopharma clients. Founded in 2001, its mission is to de-risk and accelerate the pre-clinical biologics pipeline for partners by leveraging proprietary platforms like CDRx® for humanization and RAMP® for affinity maturation. The company's strategy is built on deep technical expertise, a collaborative partnership model, and a proven track record of delivering high-quality, developable antibody candidates for hundreds of client projects.

Integrated antibody discovery and engineering platform featuring proprietary technologies for humanization (CDRx®) and affinity maturation (RAMP®), alongside hybridoma, phage display, and mammalian cell line development capabilities.

Competes with large, full-service global CROs and specialized antibody discovery firms. Differentiation is achieved through an integrated end-to-end offering, proprietary platforms (CDRx®, RAMP®), and a collaborative partnership model focused on early-stage developability.